Compare Fox Corp Class A (FOXA) vs Novo Nordisk A/S (NVO) Price & Performance

FOXA stock trades at $61.69, down 2.74% today, amid a bullish technical setup with strong support at $60. The company reported robust Q4 2026 results, beating earnings estimates with $1.79 EPS versus $1.44 expected, driven by World Cup advertising and Tubi streaming growth. Revenue rose 28% year-over-year to $4.21 billion in the quarter. Analyst sentiment is evenly split between Buy and Hold ratings, with a consensus price target of $65.33.

The outlook remains positive given strong ad demand and digital momentum, but risks include higher sports costs and reliance on major events. Earnings growth and streaming execution are key catalysts for further upside, though valuation multiples appear reasonable with a P/E of 16.18.

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.